Abstract：【Objective】 To investigate the clinical efficacy of Xinmailong injection combined with Ribavirin in the treatment of viral Myocarditis with cardiac insufficiency. 【Methods】From September 2019 to November 2021, 106 patients with viral myocarditis and cardiac insufficiency caused by coxsackie virus infection in our hospital were selected and divided into an observation group and a control group according to the different treatment methods, with 53 cases in each group. The control group was treated with Ribavirin, and the observation group was treated with Xinmailong injection on the basis of the control group. The clinical efficacy, ultrasonic cardiac function indexes [left ventricular Ejection fraction (LVEF), left ventricular short axis shortening rate (FS), left ventricular end diastolic diameter (LVEDD), cardiac index (CI)], serum brain natriuretic peptide (BNP), Superoxide dismutase (SOD), Malondialdehyde (MDA), and glutathione (GSH) levels were compared between the two groups. 【Results】The total clinical effective rate of the observation group was 96.23% (51/53), which was higher than 81.13% (43/53) of the control group, with a statistically significant difference (P<0.05). After treatment, LVEF, FS, and CI in both groups were higher than before treatment, while the observation group was higher than the control group (P<0.05); The LVEDD of the two groups was lower than before treatment, while the observation group was lower than the control group (P<0.05); The levels of serum BNP, CK-MB, LDH, and CK in the two groups were lower than before treatment, while those in the observation group were lower than those in the control group (P<0.05); The serum MDA levels in both groups were lower than before treatment, while those in the observation group were lower than those in the control group (P<0.05); The serum SOD and GSH levels in both groups were higher than before treatment, while the observation group was higher than the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two group (P>0.05). 【Conclusion】 Xinmailong injection combined with Ribavirin has a better clinical effect in the treatment of viral Myocarditis with cardiac insufficiency, which can improve the cardiac function of patients and improve the oxidative stress state of the body.
王文静. 心脉隆注射液联合利巴韦林治疗病毒性心肌炎伴心功能不全患者的临床疗效[J]. 医学临床研究, 2023, 40(7): 1036-1038.
WANG Wen-jing. Clinical Efficacy of Xinmailong Injection Combined with Ribavirin in the Treatment of Viral Myocarditis with Cardiac Insufficiency. JOURNAL OF CLINICAL RESEARCH, 2023, 40(7): 1036-1038.
2023, Vol. 40 
